Ionic conductivity in multiply substituted ceria-based electrolytes

The authors thank the University of St Andrews and the UK Engineering and Physical Sciences Research Council for the PhD studentship for AVC-A (grant code: EP/M506631/1).Cerias, appropriately doped with trivalent rare earth ions, have high oxide ion conductivity and are attractive SOFC (solid oxide fuel cell) electrolytes. Here, seven compositions of Ce0.8SmxGdyNdzO1.9 (where x, y and z = 0.2, 0.1, 0.0667 or 0 and x + y + z = 0.2) are synthesised using a low temperature method in order to determine the effect of multiple doping on microstructure and conductivity. Analysis using scanning and transmission electron microscopy, inductively coupled plasma mass spectrometry, X-ray diffraction and impedance spectroscopy is carried out. Crystallite sizes are determined in the powders and relative densities and grain size distributions were obtained in sintered pellets. Total, bulk and grain boundary conductivities are obtained using impedance spectroscopy and corresponding activation energies and enthalpies of ion migration and defect association are calculated. The highest total conductivity observed at 600 °C is 1.80 Sm−1 for Ce0.8Sm0.1Gd0.1O1.9 and an enhancement effect on conductivity for this combination of co-dopants between 300 °C and 700 °C relative to the singly doped compounds - Ce0.8Sm0.2O1.9 and Ce0.8Gd0.2O1.9 - is seen. This has interesting implications for their application as SOFC electrolytes, especially at intermediate temperatures.PostprintPeer reviewe

High-throughput sequencing offers insight into mechanisms of resource partitioning in cryptic bat species

Sympatric cryptic species, characterized by low morphological differentiation, pose a challenge to understanding the role of interspecific competition in structuring ecological communities. We used traditional (morphological) and novel molecular methods of diet analysis to study the diet of two cryptic bat species that are sympatric in southern England (Plecotus austriacus and P. auritus) (Fig. 1). Using Roche FLX 454 (Roche, Basel, CH) high-throughput sequencing (HTS) and uniquely tagged generic arthropod primers, we identified 142 prey Molecular Operational Taxonomic Units (MOTUs) in the diet of the cryptic bats, 60% of which were assigned to a likely species or genus. The findings from the molecular study supported the results of microscopic analyses in showing that the diets of both species were dominated by lepidopterans. However, HTS provided a sufficiently high resolution of prey identification to determine fine-scale differences in resource use. Although both bat species appeared to have a generalist diet, eared-moths from the family Noctuidae were the main prey consumed. Interspecific niche overlap was greater than expected by chance (Ojk= 0.72, P < 0.001) due to overlap in the consumption of the more common prey species. Yet, habitat associations of nongeneralist prey species found in the diets corresponded to those of their respective bat predator (grasslands for P. austriacus, and woodland for P. auritus). Overlap in common dietary resource use combined with differential specialist prey habitat associations suggests that habitat partitioning is the primary mechanism of coexistence. The performance of HTS is discussed in relation to previous methods of molecular and morphological diet analysis. By enabling species-level identification of dietary components, the application of DNA sequencing to diet analysis allows a more comprehensive comparison of the diet of sympatric cryptic species, and therefore can be an important tool for determining fine-scale mechanisms of coexistence

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2–4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Oxygen ion conductivity in ceria-based electrolytes co-doped with samarium and gadolinium

The authors thank the University of St Andrews and the UK Engineering and Physical Sciences Research Council for the PhD studentship for AVC-A (grant code: EP/M506631/1). Electron microscopy was performed at the Electron Microscope Facility, University of St Andrews.In a systematic study, two compositional series of ceria-based oxides, both co-doped with Sm and Gd, were synthesised using a low temperature method and evaluated as oxygen ion-conducting electrolytes for Intermediate Temperature Solid Oxide Fuel Cells (IT-SOFCs). Series one, Ce1-2xSmxGdxO2-x, had equal concentrations of Sm and Gd but varying total dopant concentration. Series two, Ce0.825SmxGd0.175-xO1.9125, had a fixed total dopant concentration but the Sm:Gd concentration ratio was varied. The materials were characterised using scanning and transmission electron microscopy, inductively coupled plasma mass spectrometry and X-ray diffraction. Impedance spectra were recorded on dense pellets of these materials. From these, total, bulk and grain boundary conductivities and capacitances along with activation energies, pre-exponential constants and enthalpies of ion migration and defect association were obtained. These gave a detailed insight into the fundamental conduction processes in the materials. Ce0.825Sm0.0875Gd0.0875O1.9125 had the highest total ionic conductivity at temperatures of 550 °C and above and also demonstrated an enhanced conductivity with respect to its singly-doped parent compounds, Ce0.825Sm0.175O1.9125 and Ce0.825Gd0.175O1.9125, at 400 °C and above. This compares favourably with previously-reported values and has promising implications for the development of IT-SOFCs.PostprintPeer reviewe

Substituted ceria materials for applications in solid oxide fuel cells

Cerias, appropriately doped with trivalent rare earth ions in particular, can have high oxide ion conductivity and are attractive as both SOFC (solid oxide fuel cell) electrolytes and anodes. Here, four groups of candidate electrolyte materials were synthesised using a low temperature method in order to determine the effect of multiple doping on their microstructure and ionic conductivity. In an initial study, seven compositions of Ce₀.₈SmₓGd[sub]yNd[sub]zO₁.₉ (where x, y and z = 0.2, 0.1, 0.0667 or 0 and x + y + z = 0.2) were synthesised and the properties of multiply-doped materials were compared with the corresponding singly-doped parent materials. The effect of co-doping with Gd and Sm was investigated in more detail by preparing and studying five compositions of Ce₁₋₂ₓSmₓGdₓO₂₋ₓ (where x = 0.125, 0.1, 0.0875, 0.075 or 0.05) and seven compositions of Ce₀.₈₂₅SmₓGd₀.₁₇₅₋ₓO₁.₉₁₂₅ (where x = 0.175, 0.14, 0.105, 0.0875, 0.07, 0.035 or 0). The effect of additional doping with a divalent ion- Ca²⁺- was studied in six compositions of Ce[sub](0.825+y)Sm[sub](0.0875-y)Gd[sub](0.0875-y)Ca[sub]yO₁.₉₁₂₅ (where y = 0, 0.00875, 0.0175, 0.02625, 0.035 or 0.04375). The materials were characterised using scanning and transmission electron microscopy, inductively coupled plasma mass spectrometry and X-ray diffraction. Crystallite sizes were determined in the powders and relative densities and grain size distributions were obtained in sintered pellets. Total, bulk and grain boundary conductivities were obtained using impedance spectroscopy and corresponding activation energies and enthalpies of ion migration and defect association were calculated. The most promising material for SOFCs operating at intermediate temperatures was found to be Ce₀.₈₂₅Sm₀.₀₈₇₅Gd₀.₀₈₇₅O₁.₉₁₂₅ which had a total conductivity at 600 °C of 2.23 S m⁻¹. Lastly, doped ceria materials, primarily Ce₀.₈Sm₀.₂O₁.₉, were employed as catalytic supports for Pd and PdO nanoparticles and these were investigated as SOFC anode materials

Ionic conductivity in multiply substituted ceria-based electrolytes

Cerias, appropriately doped with trivalent rare earth ions, have high oxide ion conductivity and are attractive SOFC (solid oxide fuel cell) electrolytes. Here, seven compositions of Ce0.8SmxGdyNdzO1.9 (where x, y and z = 0.2, 0.1, 0.0667 or 0 and x + y + z = 0.2) are synthesised using a low temperature method in order to determine the effect of multiple doping on microstructure and conductivity. Analysis using scanning and transmission electron microscopy, inductively coupled plasma mass spectrometry, X-ray diffraction and impedance spectroscopy is carried out. Crystallite sizes are determined in the powders and relative densities and grain size distributions were obtained in sintered pellets. Total, bulk and grain boundary conductivities are obtained using impedance spectroscopy and corresponding activation energies and enthalpies of ion migration and defect association are calculated. The highest total conductivity observed at 600 °C is 1.80 Sm−1 for Ce0.8Sm0.1Gd0.1O1.9 and an enhancement effect on conductivity for this combination of co-dopants between 300 °C and 700 °C relative to the singly doped compounds - Ce0.8Sm0.2O1.9 and Ce0.8Gd0.2O1.9 - is seen. This has interesting implications for their application as SOFC electrolytes, especially at intermediate temperatures

Oxygen ion conductivity in ceria-based electrolytes co-doped with samarium and gadolinium

In a systematic study, two compositional series of ceria-based oxides, both co-doped with Sm and Gd, were synthesised using a low temperature method and evaluated as oxygen ion-conducting electrolytes for Intermediate Temperature Solid Oxide Fuel Cells (IT-SOFCs). Series one, Ce1-2xSmxGdxO2-x, had equal concentrations of Sm and Gd but varying total dopant concentration. Series two, Ce0.825SmxGd0.175-xO1.9125, had a fixed total dopant concentration but the Sm:Gd concentration ratio was varied. The materials were characterised using scanning and transmission electron microscopy, inductively coupled plasma mass spectrometry and X-ray diffraction. Impedance spectra were recorded on dense pellets of these materials. From these, total, bulk and grain boundary conductivities and capacitances along with activation energies, pre-exponential constants and enthalpies of ion migration and defect association were obtained. These gave a detailed insight into the fundamental conduction processes in the materials. Ce0.825Sm0.0875Gd0.0875O1.9125 had the highest total ionic conductivity at temperatures of 550 °C and above and also demonstrated an enhanced conductivity with respect to its singly-doped parent compounds, Ce0.825Sm0.175O1.9125 and Ce0.825Gd0.175O1.9125, at 400 °C and above. This compares favourably with previously-reported values and has promising implications for the development of IT-SOFCs.</p